SCHEMBL17075141

SCHEMBL17075141

NC(=O)CN1CCC(C2CCC2)c2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
TSHR P16473 3/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP2C19 P33261 1/20 0.38
OPRK1 P41145 1/20 0.38
GAA P10253 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
CREBBP Q92793 1/20 0.35
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
CHRM1 P11229 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17075119 0.94 ALDH1A1 (0.40) ALDH1A1TSHRMAPTKDM4EMEN1
SCHEMBL17075125 0.88 ALDH1A1 (0.39) ALDH1A1TSHRMAPTKDM4EMEN1
SCHEMBL17075131 0.88 ALDH1A1 (0.38) ALDH1A1TSHRMAPTKDM4EMEN1
SCHEMBL17075104 0.85 ALDH1A1 (0.38) ALDH1A1TSHRMAPTKDM4EMEN1
SCHEMBL17075110 0.81 ALDH1A1 (0.36) ALDH1A1TSHRMAPTKDM4EMEN1
SCHEMBL17075090 0.79 SIGMAR1 (0.37) ALDH1A1MEN1ALOX15KMT2A
SCHEMBL17075184 0.77 ALDH1A1 (0.39) ALDH1A1TSHRMAPTKDM4EMEN1
SCHEMBL17075232 0.76 CYP2C19 (0.39) ALDH1A1TSHRMAPTKDM4EMEN1
SCHEMBL17075097 0.76 SIGMAR1 (0.45) ALDH1A1CYP2C19DRD2
SCHEMBL17075236 0.76 CYP2C19 (0.40) ALDH1A1TSHRMAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3116873-B1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL ABBVIE DEUTSCHLAND (DE) 2018-02-28 EP disclosed
US-20170158693-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL ABBVIE DEUTSCHLAND (DE) 2017-06-08 US disclosed
US-9573950-B2 Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2017-02-21 US disclosed
US-20150259343-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL AbbVie Deutschland GmbH & Co. KG (DE) 2015-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158693-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL HTR2C, HTR2A, HTR5A ALDH1A1 949/4885TSHR 385/4885MAPT 3762/4885
US-20150259343-A1 HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL HTR2C, HTR2A, HTR5A ALDH1A1 949/4885TSHR 385/4885MAPT 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.